CAMBRIDGE, UK (2019-11-29) – ProteinLogic, the biomarker discovery and exploitation company, has been selected to represent the UK on the UKRI Global Business Innovation Programme (GBIP) in precision medicine on a mission to China.

The GBIP is geared exclusively for Precision Medicine businesses working with technologies that enable early and accurate diagnosis to inform patient treatment, as well as the availability of targeted therapies. It aims to help innovative UK businesses develop relationships with partners in China, allowing them to gain a foothold in this market set for extensive growth. It is specifically meant to showcase the best of British science and to build international collaborative partnerships that deliver sustained economic and health benefits in both countries.

ProteinLogic was selected out of a large number of applicants due to its innovative ImmiPrint® technology and its applicability in Tuberculosis diagnosis, a major health issue in China. The company is one of only 15 participants selected for this year’s Programme.

Commenting on the news, Dr Nicolas Huber, CEO of ProteinLogic, stated: “We are very pleased that ProteinLogic has been selected to represent the UK in the prestigious GBIP mission to China. This is a key target market for our innovative diagnostic for Tuberculosis, and we are delighted by the recognition our technology and company have been getting in the fight against this terrible disease. We are looking forward to forming strong and long-lasting collaborations in China, particularly with commercial parties interested in commercializing our test in the region.”

The mission is scheduled for the end of February 2020, and will visit Shanghai and Wuxi.